title: Incidence and patterns of rejection using different induction therapies in liver transplant recipients.
authors.affiliation: Liver Transplant Program, Toronto Hospital, University of Toronto, Canada.
authors.forename: M
authors.initials: M
authors.lastname: Elkashab
authors.forename: M
authors.initials: M
authors.lastname: Reizig
authors.forename: P D
authors.initials: PD
authors.lastname: Greig
authors.forename: R
authors.initials: R
authors.lastname: Cameron
authors.forename: M J
authors.initials: MJ
authors.lastname: Phillips
authors.forename: S
authors.initials: S
authors.lastname: Chung
authors.forename: M
authors.initials: M
authors.lastname: Cattral
authors.forename: G
authors.initials: G
authors.lastname: Levy
mesh_terms: D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001707:Biopsy, Needle; D016572:Cyclosporine / Q000097:blood / Q000627:therapeutic use; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D015994:Incidence; D008111:Liver Function Tests; D016031:Liver Transplantation / Q000276:immunology* / Q000473:pathology / Q000502:physiology; D008297:Male; D008776:Methylprednisolone Hemisuccinate / Q000627:therapeutic use; D016853:Muromonab-CD3 / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D012189:Retrospective Studies
chemical_list: D000961:Antilymphocyte Serum; D016853:Muromonab-CD3; D008776:Methylprednisolone Hemisuccinate; D016572:Cyclosporine; D011241:Prednisone